Allogene Therapeutics · 3 days ago
Senior Associate Scientist, Analytical Development
Wonder how qualified you are to the job?
BiotechnologyHealth Diagnostics
Insider Connection @Allogene Therapeutics
Responsibilities
Perform flow cytometry analysis for cell therapy products.
Maintain, calibrate, and operate analytical instruments. Maintain sample inventories.
Ensure high-quality, timely documentation in electronic laboratory notebooks (ELN) with great attention to details.
Coherently summarize and communicate experiments and findings and present study results at team meetings to internal stakeholders.
Assist in analytical method optimization, development, and qualification in support of product and process development and product characterization.
Demonstrate strong accountability, organizational and interpersonal skills, and apply sound scientific and technical experience.
Work collaboratively with cross-functional teams to meet deadline-dependent milestones and advance the development of Allogene’s CAR T programs.
Other duties as assigned.
Qualification
Find out how your skills align with this job's requirements. If anything seems off, you can easily click on the tags to select or unselect skills to reflect your actual expertise.
Required
Bachelor’s or Master’s Degree with 3+ years of relevant cell biology, immunology or biochemistry experience.
Ability to work independently and as part of a team.
Experience with flow cytometry and analysis is required.
Self-motivated, organized and detail-orientated, with a positive “can-do” attitude towards assigned tasks is expected.
Candidates must be authorized to work in the U.S.
Preferred
Experience with data analysis tools such as Spotfire, FlowJo, FACSuite, and Microsoft Excel a plus.
Working knowledge of quality control and assay qualification is a plus.
Company
Allogene Therapeutics
Allogene Therapeutics is a biotechnology company catalyzing cancer treatment through the development of CAR T therapy.
Funding
Current Stage
Public CompanyTotal Funding
$1.01BKey Investors
Perceptive Advisors
2024-05-13Post Ipo Equity· $110M
2019-11-01Post Ipo Equity· $250M
2018-10-11IPO· nasdaq:ALLO
Recent News
2024-05-13
2024-05-13
2024-04-13
Company data provided by crunchbase